A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of
ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the
standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN.
The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial
Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension
(OLE) Period of up to 2 years.
Safety will be monitored throughout the study.
Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.